bullish

Cogstate Ltd

Cogstate - Remembering What Matters

293 Views04 Mar 2023 08:13
Broker
CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m rev deferred to FY24+.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 19-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
CCZ Statton Equities
External broker reports(aggregated public sources)
CCZ Statton Equities
AustraliaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x